Proton Pump

Related Products

Proton pump is an integral membrane protein that is capable of moving protons across a biological membrane. Mechanisms are based on conformational changes of the protein structure or on theQ cycle. In cell respiration, the proton pump uses energy to transport protons from the matrix of the mitochondrion to the inter-membrane space. It is an active pump, that generates a protonconcentration gradient across the inner mitochondrial membrane, because there are more protons outside the matrix than inside. The difference in pH and electric charge (ignoring differences inbuffer capacity) creates an electrochemical potential difference that works similar to that of a battery or energy storing unit for the cell. The process could also be seen as analogous to cycling uphill or charging a battery for later use, as it produces potential energy. The proton pump does not create energy, but forms a gradient that stores energy for later use.

Proton Pump Related Products (130)
Antibodies (1)

By Effects:	Inhibitors (121) Antagonists (3) Activators (2)

Cat. No.	Product Name	Effect	Purity	Chemical Structure

HY-117025A

Manzamine A hydrochloride	Inhibitor	99.66%
Manzamine A hydrochloride, an orally active beta-carboline alkaloid, inhibits specifically GSK-3β and CDK-5 with IC₅₀s of 10.2 μM and 1.5 μM, respectively. Manzamine A hydrochloride targets vacuolar ATPases and inhibits autophagy in pancreatic cancer cells. Manzamine A hydrochloride has antimalarial and anticancer activities. Manzamine A hydrochloride also shows potent activity against HSV-1.

HY-100560S

Abscisic acid-d₆	Inhibitor	98.69%
Abscisic acid-d₆ is deuterium labeled Abscisic acid. Abscisic acid inhibits proton pump (H+-ATPase)[1].

HY-A0213A

Tiludronate disodium	Inhibitor	99.84%
Tiludronate (Tiludronic Acid) disodium, an orally active bisphosphonate, can act an osteoregulator. Tiludronate is used for the research of the metabolic bone disorders. Tiludronate is a potent inhibitor of the osteoclast vacuolar H(+)-ATPase. Antiresorptive and anti-inflammatory properties.

HY-W003467

Rabeprazole Sulfide	Inhibitor	98.09%
Rabeprazole Sulfide is an active metabolite of Rabeprazole. Rabeprazole is a proton pump inhibitor that suppresses gastric acid secretion through an interaction with (H⁺/K⁺)-ATPase in gastric parietal cells. Rabeprazole markedly inhibits the motility of *H. pylori*. Rabeprazole has the potential for various peptic diseases treatment.

HY-B2145A

Ilaprazole sodium hydrate	Inhibitor	99.15%
Ilaprazole (IY-81149) sodium hydrate is an orally active proton pump inhibitor. Ilaprazole sodium hydrate irreversibly inhibits H⁺/K⁺-ATPase in a dose-dependent manner with an IC₅₀ of 6 μM in rabbit parietal cell preparation. Ilaprazole sodium hydrate is used for the research of gastric ulcers. Ilaprazole sodium hydrate is also a potent TOPK (T-lymphokine-activated killer cell-originated protein kinase) inhibitor.

HY-B0656S

Rabeprazole-d₄	Inhibitor
Rabeprazole-d₄ is a deuterium labeled Rabeprazole. Rabeprazole is a second-generation proton pump inhibitor (PPI) that irreversibly inactivates gastric H+/K+-ATPase. Rabeprazole induces apoptosis. Rabeprazole acts as an uridine nucleoside ribohydrolase (UNH) inhibitor with an IC50 of 0.3 μM. Rabeprazole can be used for the research of gastric ulcerations and gastroesophageal reflux[1][2][3].

HY-100412

Linaprazan	Inhibitor	99.61%
Linaprazan (AZD0865) can inhibit H+,K+ -ATPase in the stomach through K+ competitive binding, (IC₅₀: 1.0 ± 0.2 μM), it has a strong inhibitory effect on acid. Linaprazan (AZD0865) can be used for research on reflux esophagitis with oral activity.

HY-W008614

Lansoprazole sulfone	Inhibitor	99.52%
Lansoprazole sulfone (AG-1813) is an orally active and selective inhibitor of H⁺, K⁺-ATPase. Lansoprazole sulfone can significantly stimulates gastric acid secretion by inhibiting H⁺, K⁺-ATPase. Lansoprazole sulfone has potential applications in duodenal ulcer, gastric ulcer, gastroesophageal reflux disease and Zolinger Ellison disease.

HY-B0656AS

Rabeprazole-d₄ sodium	Inhibitor	98.61%
Rabeprazole-d₄ (sodium) is the deuterium labeled Rabeprazole sodium. Rabeprazole sodium (LY307640 sodium) is a second-generation proton pump inhibitor (PPI) that irreversibly inactivates gastric H+/K+-ATPase. Rabeprazole sodium induces apoptosis. Rabeprazole sodium acts as an uridine nucleoside ribohydrolase (UNH) inhibitor with an IC50 of 0.3 μM. Rabeprazole sodium can be used for the research of gastric ulcerations and gastroesophageal reflux[1][2][3].

HY-108970

Bafilomycin D	Inhibitor	99.30%
Bafilomycin D is a specific inhibitor of vacuolar-type ATPase (V-ATPase). Bafilomycin D has antimicrobial, insecticidal, herbicidal and cytotoxic activity.

HY-P3278

Caloxin 2A1	Inhibitor	99.82%
Caloxin 2A1 is an extracellular plasma membrane Ca²⁺-ATPase (PMCA) peptide inhibitor. Caloxin 2A1 does not affect basal Mg²⁺-ATPase or Na⁺-K⁺-ATPase.

HY-13662S

Lansoprazole-d₄	Inhibitor	99.82%
Lansoprazole-d₄ is a deuterium labeled Lansoprazole. Lansoprazole is a proton pump inhibitor which prevents the stomach from producing acid[1].

HY-19223

Pumaprazole	Antagonist	99.75%
Pumaprazole is a reversible proton pump antagonist.

HY-13662BS

(R)-Lansoprazole-d₄	Inhibitor	99.13%
(R)-Lansoprazole-d₄ is deuterium labeled (R)-Lansoprazole. (R)-Lansoprazole is the R enantiomer of Lansoprazole, Lansoprazole (AG 1749) is an orally active proton pump inhibitor which prevents the stomach from producing acid. Lansoprazole (AG 1749) is a potent brain penetrant neutral sphingomyelinase (N-SMase) inhibitor (exosome inhibitor)[1][2].

HY-N7031

(±)-Vasicine	Inhibitor	99.92%
(±)-Vasicine is the racemate of Vasicine. Vasicine (Peganine) significantly inhibits H⁺-K⁺-ATPase activity?in vitro?with an IC₅₀ of 73.47?μg/mL. Anti-ulcer activity. Vasicine shows significant anti-secretory, antioxidant and?cytoprotective?effect.

HY-B0113S3

Omeprazole-¹³C,d₃	Inhibitor	98.00%
Omeprazole-¹³C,d₃ is a ¹³C-labeled and deuterium labeled Omeprazole. Omeprazole (H 16868), a proton pump inhibitor (PPI), is available for treatment of acid-related gastrointestinal disorders. Omeprazole shows competitive inhibition of CYP2C19 activity with a Ki of 2 to 6 μM[1]. Omeprazole also inhibits growth of Gram-positive and Gram-negative bacteria[2].Omeprazole is a potent brain penetrant neutral sphingomyelinase (N-SMase) inhibitor (exosome inhibitor)[3].

HY-117025

Manzamine A	Inhibitor
Manzamine A, an orally active beta-carboline alkaloid, inhibits specifically GSK-3β and CDK-5 with IC₅₀s of 10.2 μM and 1.5 μM, respectively. Manzamine A targets vacuolar ATPases and inhibits autophagy in pancreatic cancer cells. Manzamine A has antimalarial and anticancer activities. Manzamine A also shows potent activity against HSV-1.

HY-13100

PF 03716556	Antagonist	99.69%
PF 03716556 is a potent, selective, competitive and reversible acid pump (H⁺,K⁺-ATPase) antagonist with pIC₅₀s of 6.026, 6.038 and 6.009 for porcine, canine, and human recombinant gastric H⁺,K⁺-ATPase, respectively. PF 03716556 is inactive against other receptors, ion channels, and enzymes. PF 03716556 has the potential for gastroesophageal reflux disease research.

HY-17021B

Esomeprazole potassium salt	Inhibitor	98.18%
Esomeprazole potassium salt ((S)-Omeprazole potassium salt) is a potent and orally active proton pump inhibitor and reduces acid secretion through inhibition of the H⁺, K⁺-ATPase in gastric parietal cells. Esomeprazole potassium salt has the potential for symptomatic gastroesophageal reflux disease research.

HY-109546

Omeprazole magnesium	Inhibitor
Omeprazole magnesium is an orally active proton pump inhibitor (PPI) and can suppress gastric acid. Omeprazole magnesium can be used for acid reflux-related symptoms and frequent heartburn research.

Name
Email *

	Sorry, but the email address you supplied was invalid.

Proton Pump

Proton Pump

Proton Pump Related Products (130)

Antibodies (1)

Proton Pump Related Products (130):